Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Ono, Sachiko; Tanioka, Miki; Fujisawa, Akihiko; Tanizaki, Hideaki; Matsumura, Yasuhiro

doi:10.1001/archdermatol.2011.2819

Cited by 15 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strong effect of rapamycin on lymphatic-based lesions is consistent with our findings of the of cutaneous lymphangiosarcoma development in Tsc1 iΔEC mice as well as the requirement of mTORC1 for tumor maintenance. Several anti-VEGF/VEGFR drugs, including axitinib are in various phases of clinical trial and some have already shown activity against angiosarcoma (Agulnik et al, 2013; Ono et al, 2012). Inhibition of VEGFs by shRNA or axitinib significantly reduced growth of vascular tumors derived from our Tsc1 iΔEC mouse model.…”

Section: Discussionmentioning

confidence: 99%

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

et al. 2015

View full text Add to dashboard Cite

Summary Angiosarcoma/lymphangiosarcoma is a rare malignancy with poor prognosis. We generated a mouse model with inducible endothelial cell-specific deletion of Tsc1 to examine mTORC1 signaling in lymphangiosarcoma. Tsc1 loss increased retinal angiogenesis in neonates, and led to endothelial proliferative lesions from vascular malformations to vascular tumors in adult mice. Sustained mTORC1 signaling was required for lymphangiosarcoma development and maintenance. Increased VEGF expression in tumor cells was seen, and blocking autocrine VEGF signaling abolished vascular tumor development and growth. We also found significant correlations between mTORC1 activation and VEGF, HIF1α, and c-Myc expression in human angiosarcoma samples. These studies demonstrated critical mechanisms of aberrant mTORC1 activation in lymphangiosarcoma, and validate the mice as a valuable model for further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, further supportive reagents are necessary for the treatment of AS with DTX. More recently, several reports suggested that inhibiting the angiogenic factor VEGF/VEGFR pathway might be a promising therapy for AS [10,11,12]. Therefore, in this report, we focused on MMP-9, which is a stromal factor that remodels the extracellular matrix and promotes the sprouting and growth of new blood vessels by making VEGF available to the VEGFR-2/flk receptor on endothelial cells [13].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Immunosuppressive and Cytotoxic Cells in Angiosarcoma: Development of a Possible Supportive Therapy for Angiosarcoma

et al. 2013

View full text Add to dashboard Cite

An imbalance of immunosuppressive and cytotoxic cells plays an important role in inhibiting the anti-tumor immune response of the tumor-bearing host. The purpose of this study was to elucidate the involvement of immunosuppressive cells, such as regulatory T cells and CD163+ M2 macrophages as well as cytotoxic cells, such as granulysin-bearing cells and TIA-1+ cells in cutaneous angiosarcoma (AS) by immunohistochemical staining. In addition we evaluated the potencies of bisphosphonate, which was previously reported to suppress the expression of matrix metalloproteinase 9 (MMP-9), as a supportive therapy for AS together with docetaxel in 6 cases of cutaneous AS. These findings suggest that a high number of immunosuppressive cells might be related to the prognosis of AS, and that a combination of docetaxel with bisphosphonate risedronate sodium might be effective for MMP-9-expressing AS.

show abstract

“… 2 Surgery could be the most effective method of treatment, but for advanced and metastatic angiosarcoma, chemotherapy would be the main choice. Considering that the prevalence of angiosarcomas is high in elderly patients aged between 70 and 75 years 3 and that the toxicities associated with combined chemotherapy often require treatment cessation, patients with angiosarcomas require newer, safer, and more effective treatments.…”

Section: Introductionmentioning

confidence: 99%

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Ji¹,

Liu²,

Yang

2016

OTT

View full text Add to dashboard Cite

Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of advanced angiosarcoma that was successfully treated with apatinib, an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). To our knowledge, this is the first case to report the successful use of apatinib for angiosarcoma. Furthermore, the administration of apatinib results in fewer toxic effects than traditional cytotoxic chemotherapy. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and that VEGFR-2 plays a crucial role for angiosarcoma. Apatinib may be an additional option for angiosarcoma especially for the aged and patients with poor performance status. Further prospective studies are required to optimize the use of apatinib in patients with angiosarcoma and to identify which patients will benefit from the agent.

show abstract

Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Cited by 15 publications

References 13 publications

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

Comparison of Immunosuppressive and Cytotoxic Cells in Angiosarcoma: Development of a Possible Supportive Therapy for Angiosarcoma

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Contact Info

Product

Resources

About